Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 7/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | LIPE | Q05469 | 7/20 | 0.35 |
| ▸ | JAK2 | O60674 | 2/20 | 0.33 |
| ▸ | BTK | Q06187 | 2/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | F11 | P03951 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.32 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13601622 | 0.85 | JAK2 (0.40) | LPLLIPGLIPEJAK2BTK | |
| SCHEMBL29382961 | 0.84 | LPL (0.43) | LPLLIPGHSD11B1LIPEF2 | |
| SCHEMBL9755 | 0.84 | LPL (0.43) | LPLLIPGHSD11B1LIPEF2 | |
| SCHEMBL24457824 | 0.83 | LPL (0.36) | LPLLIPGLIPEJAK2BTK | |
| SCHEMBL23043096 | 0.83 | JAK2 (0.39) | LPLLIPGLIPEJAK2BTK | |
| SCHEMBL31440036 | 0.83 | LPL (0.39) | LPLLIPGLIPEJAK2BTK | |
| SCHEMBL17315234 | 0.83 | JAK2 (0.41) | LPLLIPGLIPEJAK2BTK | |
| SCHEMBL4879042 | 0.83 | LPL (0.39) | LPLLIPGLIPEJAK2BTK | |
| SCHEMBL23043322 | 0.80 | LPL (0.36) | LPLLIPGLIPEJAK2BTK | |
| SCHEMBL29418644 | 0.80 | LPL (0.36) | LPLLIPGLIPEJAK2BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298894-A1 | AMINO ACID COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298894-A1 | AMINO ACID COMPOUNDS | S1PR1, S1PR2, S1PR5 | LPL 2323/4885LIPG 1130/4885HSD11B1 2424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.